Arvinas Inc.

Contributing Author

Recent Articles by Arvinas Inc.

Nov-05	Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update ARVN GlobeNewswire
Nov-03	Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting ARVN GlobeNewswire
Nov-03	Arvinas to Participate in Upcoming Investor Conferences ARVN GlobeNewswire
Oct-29	Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 ARVN GlobeNewswire
Oct-24	Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ARVN GlobeNewswire
Oct-22	Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ARVN GlobeNewswire
Oct-20	Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy ARVN GlobeNewswire
Oct-13	Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress ARVN GlobeNewswire
Oct-05	Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders ARVN GlobeNewswire
Oct-01	Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders ARVN GlobeNewswire
Sep-17	Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation ARVN GlobeNewswire
Aug-29	Arvinas to Participate in Upcoming Investor Conferences ARVN GlobeNewswire
Aug-08	Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer ARVN GlobeNewswire
Aug-06	Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update ARVN GlobeNewswire
Jul-30	Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 ARVN GlobeNewswire
Jul-09	Arvinas Announces Retirement of Chief Executive Officer and Succession Plan ARVN GlobeNewswire
Jun-13	Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress ARVN GlobeNewswire
Jun-06	Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer ARVN GlobeNewswire
Jun-05	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting ARVN GlobeNewswire
May-31	Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer ARVN GlobeNewswire
May-30	Arvinas to Present at Jefferies Global Healthcare Conference ARVN GlobeNewswire

Arvinas Inc.

Recent Articles by Arvinas Inc.

Upgrade your FINVIZ experience